荃信生物-B（02509.HK）今日盘中股价出现大幅下挫，跌幅达5.38%，引发市场关注。截至盘中某时刻，该股报8.600港元/股，成交量7.52万股，换手率0.03%，振幅5.05%。资金流向方面，该股出现明显净流出，流入资金19.1394万港元，流出资金47.8374万港元。
荃信生物-B是一家专注于生物制药的中国公司，主要从事自体免疫及过敏性疾病生物疗法的研发。公司目前有两款核心产品QX002N和QX005N，均为自主开发。值得注意的是，QX005N于2024年1月被药审中心纳入突破性治疗品种（BTD）名单，显示出公司在研发方面取得了一定进展。然而，最近的财报显示公司净利润为-3.62亿港元，每股收益-1.65港元，这可能是导致投资者信心不足的原因之一。
从行业整体来看，生物技术板块今日表现疲软，整体跌幅为2.41%。荃信生物-B的股价下跌幅度超过行业平均水平，可能与公司自身经营状况以及行业整体承压有关。在当前市场环境下，投资者对生物科技公司的盈利能力和研发进展可能持谨慎态度，这也可能是导致荃信生物-B股价大跌的原因之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.